Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study
Authors
Okusaka, T.Kitano, M.
Chen, M.
Chen, J.
Ostwal, V.
McNamara, Mairead G
Breder, V.
Petrova, M.
Buchschacher, G.
Rokutanda, N.
Xiong, J.
Cohen, G.
Oh, D.
Affiliation
National Cancer Center Hospital, Tokyo, Japan; 2Wakayama Medical University,Wakayama, Japan;Issue Date
2022